Evidence map›Paper›PMID 34395813›Full record

ArticleBio-protocol2018

Zebrafish Embryo Xenograft and Metastasis Assay.

Ilkka Paatero, Sanni Alve, Silvia Gramolelli, Johanna Ivaska, Päivi M Ojala

Abstract read
In one paragraph

Article in Bio-protocol, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. XePhIR: the zebrafish xenograft phenotype interactive repository.Database : the journal of biological databases and curation · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish.Journal of visualized experiments : JoVE · 2020
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ilkka PaateroTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Sanni AlveResearch Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.
Silvia GramolelliResearch Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.
Johanna IvaskaTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Päivi M OjalaResearch Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xenograft models, and in particular the mouse xenograft model, where human cancer cells are transplanted into immunocompromised mice, have been used extensively in cancer studies. Although these models have contributed enormously to our understanding of cancer biology, the zebrafish xenograft model offers several advantages over the mouse model. Zebrafish embryos can be easily cultured in large quantities, are small and easy to handle, making it possible to use a high number of embryos for each experimental condition. Young embryos lack an efficient immune system. Therefore the injected cancer cells are not rejected, and the formation of primary tumors and micrometastases is rapid. Transparency of the embryos enables imaging of primary tumors and metastases in an intact and living embryo. Here we describe a method where GFP expressing tumor cells are injected into pericardial space of zebrafish embryos. At four days post-injection, the embryos are imaged and the formation of primary tumor and distant micrometastases are analyzed.

Indexed as

CancerEmbryoMelanomaMicrometastasesProtocolXenograftZebrafish

Identifiers

PMID34395813
PMCPMC8328589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.